Patents by Inventor Hee Lam CHAN

Hee Lam CHAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide therapy for Leber congenital amaurosis
    Patent number: 11920132
    Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: March 5, 2024
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
  • Antisense oligonucleotides for the treatment of eye disease
    Patent number: 11479771
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: October 25, 2022
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Hester Catharina Van Diepen, Janne Juha Turunen, Hee Lam Chan
  • ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME
    Publication number: 20220213478
    Abstract: The invention relates to the fields of medicine. In particular, it relates to novel antisense oligonucleotides (AONs) that are capable of skipping exon 62 from human USH2A premRNA and that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 7, 2022
    Inventors: Jim Swildens, Maarten Holkers, Sunseeahray Eugenie Elizabeth Naomi Mahakena, Kalyana Chakravarthi Dulla, Hee Lam Chan
  • OLIGONUCLEOTIDES TO TREAT EYE DISEASE
    Publication number: 20210401871
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher Syndrome type II and/or USH2A-associated non syndromic retina degeneration, especially by skipping a pseudo exon (PE40) between exon 40 and 41 in the human USH2A gene.
    Type: Application
    Filed: September 15, 2021
    Publication date: December 30, 2021
    Inventors: Hester Catharina Van Diepen, Hee Lam Chan, Janne Juha Turunen
  • Oligonucleotides to treat eye disease
    Patent number: 11123360
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher Syndrome type II and/or USH2A-associated non syndromic retina degeneration, especially by skipping a pseudo exon (PE40) between exon 40 and 41 in the human USH2Agene.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: September 21, 2021
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Hester Catharina Van Diepen, Hee Lam Chan, Janne Juha Turunen
  • OLIGONUCLEOTIDE THERAPY FOR LEBER CONGENITAL AMAUROSIS
    Publication number: 20210139905
    Abstract: Antisense oligonucleotides target the mutation in introit 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 13, 2021
    Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
  • Oligonucleotide therapy for Leber Congenital Amaurosis
    Patent number: 10889817
    Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: January 12, 2021
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
  • OLIGONUCLEOTIDES TO TREAT EYE DISEASE
    Publication number: 20200237802
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher Syndrome type II and/or USH2A-associated non syndromic retina degeneration, especially by skipping a pseudo exon (PE40) between exon 40 and 41 in the human USH2Agene.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 30, 2020
    Inventors: Hester Catharina Van Diepen, Hee Lam Chan, Janne Juha Turunen
  • ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF EYE DISEASE
    Publication number: 20200181616
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration.
    Type: Application
    Filed: February 7, 2020
    Publication date: June 11, 2020
    Inventors: Hester Catharina Van Diepen, Janne Juha Turunen, Hee Lam Chan
  • Oligonucleotides to treat eye disease
    Patent number: 10617707
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher Syndrome type II and/or USH2A-associated non syndromic retina degeneration, especially by skipping a pseudo exon (PE40) between exon 40 and 41 in the human USH2A gene.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: April 14, 2020
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Hester Catharina Van Diepen, Hee Lam Chan, Janne Juha Turunen
  • Antisense oligonucleotides for the treatment of eye disease
    Patent number: 10612025
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: April 7, 2020
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Hester Catharina Van Diepen, Janne Juha Turunen, Hee Lam Chan
  • OLIGONUCLEOTIDE THERAPY FOR LEBER CONGENITAL AMAUROSIS
    Publication number: 20200063134
    Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Application
    Filed: September 20, 2019
    Publication date: February 27, 2020
    Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
  • OLIGONUCLEOTIDES TO TREAT EYE DISEASE
    Publication number: 20190381089
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher Syndrome type II and/or USH2A-associated non syndromic retina degeneration, especially by skipping a pseudo exon (PE40) between exon 40 and 41 in the human USH2A gene.
    Type: Application
    Filed: April 25, 2017
    Publication date: December 19, 2019
    Inventors: Hester Catharina VAN DIEPEN, Hee Lam CHAN, Janne Juha TURUNEN
  • Oligonucleotide therapy for leber congenital amaurosis
    Patent number: 10421963
    Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 24, 2019
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
  • ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF EYE DISEASE
    Publication number: 20190256847
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration.
    Type: Application
    Filed: September 22, 2017
    Publication date: August 22, 2019
    Inventors: Hester Catharina Van Diepen, Janne Juha Turunen, Hee Lam Chan
  • OLIGONUCLEOTIDE THERAPY FOR LEBER CONGENITAL AMAUROSIS
    Publication number: 20180030439
    Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 1, 2018
    Inventors: Patricia Coromoto BIASUTTO, Hee Lam CHAN